Foundayo: cost, evidence, and the honest comparison
Orforglipron targets the same GLP-1 receptor as the injectables, but as a small molecule rather than a peptide — which is why it can be swallowed without the food-and-water timing rules that oral semaglutide requires.
What it's approved for#
Chronic weight management in adults, approved April 2026 — the first small-molecule GLP-1 pill in the class.
Forms and doses: Once-daily tablet, 0.8 mg through 17.2 mg, taken any time of day with no food or water restrictions.
What the research actually shows#
Approved through the FDA's National Priority Voucher pathway in April 2026 on the strength of its phase 3 programme. Because it launched recently, long-term real-world data is still accumulating — worth knowing before assuming equivalence with older options.
Sources: Eli Lilly approval announcement, April 2026 · FDA National Priority Voucher programme
Side effects, stated plainly#
Gastrointestinal effects consistent with the GLP-1 class were the most common in trials. As a recently approved medicine, its long-term safety picture is younger than semaglutide's or tirzepatide's.
What it costs#
Launch pricing is aggressive at the entry doses — $149 to $349 a month by dose through the manufacturer's channel, with promotional tiers running through the end of 2026, and it is included in Medicare's $50 Bridge copay.
| Channel | Form & dose | Med | Required fee | True monthly | Status |
|---|---|---|---|---|---|
| LillyDirect — FoundayoLOWEST LISTED | pill · 0.8 mg | $149 | — | $149 | listed |
| LillyDirect — Foundayo | pill · 2.5 mg | $149 | — | $149 | listed |
| LillyDirect — Foundayo | pill · 5.5 mg | $199 | — | $199 | listed |
| Hims & Hers | pill · from $149 | $149 | $149/mo | $298 | listed |
| Ro (Ro Body) | pill · 0.8 mg | $149 | $149/mo | $298 | listed |
| LillyDirect — Foundayo | pill · 9 mg | $299 | — | $299 | listed |
| LillyDirect — Foundayo | pill · 14.5 mg | $299 | — | $299 | listed |
| LillyDirect — Foundayo | pill · 17.2 mg | $299 | — | $299 | listed |
| Ro (Ro Body) | pill · 2.5/5.5 mg (promo) | $199 | $149/mo | $348 | listed |
| Ro (Ro Body) | pill · 9 mg | $299 | $149/mo | $448 | listed |
True monthly = medication plus any required membership fee. Cheapest listed right now: LillyDirect — Foundayo at $149/month. Full table and filters on the Foundayo cost page.
Coupon or manufacturer program?#
There is no US generic of this medication, so a discount card is negotiating against a single list price rather than a competitive market. The manufacturer's own cash-pay pharmacy is normally the cheapest legitimate route, and coupon sites advertising this drug are usually quoting the same programme back to you.
Watch for "as low as" figures that quote the best-case dose or a first-fill promotion rather than your ongoing price.
The full reasoning, including why "as low as" banners usually quote someone else's discount, is in the coupon analysis.
Keep reading#
Common questions#
How is Foundayo different from the Wegovy pill?#
Both are once-daily GLP-1 tablets, but Foundayo is a small molecule with no food or water timing rules, while oral semaglutide must be taken on an empty stomach with specific water and waiting requirements. Prices differ by dose — both are on our cost pages.
Other weight loss medications#
Wegovy · Zepbound · Ozempic · Compounded semaglutide · Compounded tirzepatide · Liraglutide · Mounjaro
Foundayo market news#
The complaint targets sharing sensitive health data with ad platforms and ROSCA billing/cancellation practices — context for anyone weighing the $149/month membership model.
The Hims dossier →Participating Part D plans now cover Wegovy (pen and pill), Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay through 2027 — below every cash price we track.
How the Bridge actually works →The proposed 503B Bulks List exclusion would close the mass-compounding era for good. Patient-specific 503A compounding continues — the legal market our index tracks at $139–$297 all-in.
The surviving market, explained →All tracked news → · Subscribe to this beat (RSS) · Fed by a daily automated scan; entries publish only after primary-source verification.
Educational and pricing journalism, not medical advice — indications, dosing, and suitability are decisions for you and a licensed clinician, and the FDA label is the authority on risks. Prices carry the verification dates shown; the provider's checkout is the final word. No link on this page earns us a commission; rankings are ordered by cost, never compensation — disclosure.